IperionX Limited Sponsored ADR (NASDAQ:IPX) Receives $53.33 Consensus Target Price from Analysts

IperionX Limited Sponsored ADR (NASDAQ:IPXGet Free Report) has earned an average recommendation of “Moderate Buy” from the six analysts that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $53.3333.

Several research firms have recently issued reports on IPX. Roth Capital set a $53.00 price objective on IperionX in a research report on Wednesday, August 5th. BTIG Research boosted their target price on IperionX from $40.00 to $55.00 and gave the stock a “buy” rating in a research note on Friday, June 5th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of IperionX in a report on Friday, July 17th.

Read Our Latest Research Report on IperionX

Insider Buying and Selling at IperionX

In related news, Chairman Todd Hannigan bought 300,000 shares of the company’s stock in a transaction that occurred on Monday, July 13th. The shares were purchased at an average cost of $3.59 per share, with a total value of $1,077,000.00. Following the transaction, the chairman directly owned 26,633,334 shares of the company’s stock, valued at approximately $95,613,669.06. This represents a 1.14% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Anastasios Arima acquired 138,720 shares of the firm’s stock in a transaction on Friday, July 10th. The stock was bought at an average price of $3.58 per share, with a total value of $496,617.60. Following the purchase, the chief executive officer directly owned 12,455,502 shares of the company’s stock, valued at $44,590,697.16. This represents a 1.13% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last 90 days, insiders bought 663,720 shares of company stock valued at $2,379,118.

Institutional Trading of IperionX

Several institutional investors and hedge funds have recently bought and sold shares of IPX. Private Advisor Group LLC increased its stake in IperionX by 69.9% in the first quarter. Private Advisor Group LLC now owns 63,111 shares of the company’s stock valued at $1,643,000 after purchasing an additional 25,964 shares during the period. JPMorgan Chase & Co. purchased a new stake in shares of IperionX during the second quarter worth approximately $66,000. Corigliano Investment Advisers LLC acquired a new stake in shares of IperionX during the fourth quarter worth $362,000. XY Capital Ltd purchased a new position in IperionX in the 4th quarter valued at $290,000. Finally, XTX Topco Ltd acquired a new position in IperionX in the 4th quarter valued at $302,000. Hedge funds and other institutional investors own 2.76% of the company’s stock.

IperionX Stock Performance

NASDAQ:IPX opened at $21.01 on Monday. The business’s fifty day moving average price is $24.27 and its 200 day moving average price is $31.93. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.03 and a quick ratio of 4.00. IperionX has a 12 month low of $20.05 and a 12 month high of $61.45.

About IperionX

(Get Free Report)

IperionX (NASDAQ: IPX) is a mineral technology company focused on the production and commercialization of high‐purity titanium and zirconium products. The company’s core activities include the development of advanced mineral sands projects and the deployment of proprietary processing technologies aimed at supplying feedstocks to aerospace, defense, additive manufacturing and battery markets.

At the heart of IperionX’s operations is the Stony Creek Project in Virginia, where the company holds significant mineral sands rights.

Further Reading

Analyst Recommendations for IperionX (NASDAQ:IPX)

Receive News & Ratings for IperionX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IperionX and related companies with MarketBeat.com's FREE daily email newsletter.